Skip to main content

Table 1 Weight, water intake and urine albumin data in lean controls and leptin-deficient (ob/ob−/−) mice

From: SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

 

Weight

Water intake (ml/mouse/day)

Urine albumin (µg/ml)

Body (g)

Heart (g)

Kidney (g)

Lean (n = 12)

 BL

28 ± 1

n.d

n.d

6.7 ± 0.6

9.5 ± 3.0 (n = 2)

 5 weeks

30 ± 1

n.d

n.d

5.0 ± 1.2

7.1 ± 2.0 (n = 3)

 10 weeks

33 ± 2

0.18 ± 0.04

0.21 ± 0.01

5.4 ± 0.7

7.6 ± 1.4 (n = 6)

ob/ob−/− untreated (n = 21)

 BL

47 ± 4**

n.d

n.d

8.2 ± 2.2*

22.7 ± 5.1 (n = 16)

 5 weeks

53 ± 6**

n.d

n.d

9.0 ± 4.0*

15.1 ± 3.1 (n = 19)

 10 weeks

60 ± 6**

0.18 ± 0.02

0.22 ± 0.03

8.9 ± 3.8**

10.95 ± 1.8 (n = 12)

ob/ob−/− treated (n = 22)

 BL

48 ± 3**

n.d

n.d

8.1 ± 1.0*

33.0 ± 4.1 (n = 16)

 5 weeks

54 ± 3**

n.d

n.d

13.5 ± 1.5*‡

7.2 ± 1.1 (n = 9)

 10 weeks

58 ± 3**

0.20 ± 0.03

0.24 ± 0.04*‡

14.4 ± 2.8**‡

5.2 ± 0.3 (n = 5)

  1. To monitor the progression of obesity, body weight was studied over time, and as a measure of animal health, water intake was recorded. Wet heart and kidney weight were also recorded at the end of the treatment period. Statistical significance within each time point by one-way ANOVA and Tukey’s post hoc. Values are presented as mean ± SD for parametric data and mean ± SEM for non-parametric data, where *p < 0.05 and **p < 0.01 and ‡p ≤ 0.05 for ob/ob−/− treated and untreated group
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840